Search - tctmd.com

Displaying 1 - 18 of 18

Sort: Relevancy | Date

Looking for a Winner Between Long-term TAVI Trials? Don’t, Experts Urge

Shelley Wood

November 27, 2023

News Daily News

Ross Procedure Offers ‘Excellent Survival’ 25 Years Out

Caitlin E. Cox

November 15, 2023

News Conference News TCT 2023

Durability, Hemodynamics Look Good for SAVR, TAVI in PARTNER 3

Michael O'Riordan

November 01, 2023

Presentation TCT 2023

TCT 396: Calcification Patterns in TAVR Explants: Informing Durability & Implications for Reintervention

Presenter: Stephanie Sellers

October 25, 2023

Presentation TCT 2023

Current Knowledge of Durability of Bioprosthetic Valves (SAVR and TAVR)

Presenter: Michael Reardon

October 25, 2023

News Conference News TCT 2023

Some Surprises in Low-Risk TAVI Follow-up: PARTNER 3 and Evolut Trials

Michael O'Riordan

October 24, 2023

News Conference News EACTS 2023

SWEDEHEART Hints at Mortality Benefit With Statins After SAVR

Michael O'Riordan

October 05, 2023

News Daily News

Balloon-Expandable Redo TAVI Shows Promise in Real-world Cohort

Yael L. Maxwell

September 06, 2023

News Conference News TVT 2023

‘Excellent’ Outcomes With Mitral ViV Procedures, Even in Lower-Risk Patients

Michael O'Riordan

June 09, 2023

Presentation TVT 2023

SAPIEN 3 TAVR Durability

Presenter: Karim Al-Azizi

June 09, 2023

Presentation TVT 2023

What Do We Actually Know About Bioprosthetic Valve Durability (SAVR and TAVR)

Presenter: Danny Dvir

June 08, 2023

News Conference News EuroPCR 2023

Five-Year PORTICO IDE Data Reassure on Outcomes, Hemodynamics

Michael O'Riordan

May 17, 2023

News Conference News ACC 2023

Self-Expanding TAVI Holds Up to Surgery Out to 3 Years in Low-Risk Patients

Todd Neale

March 05, 2023

News Conference News CRT 2023

New Durability Definitions Still Give Self-Expanding TAVI an Edge vs SAVR

Yael L. Maxwell

March 03, 2023

News Daily News

FDA Alert: Possible Early Deterioration of Abbott Trifecta SAVR Valves

Todd Neale

February 27, 2023

News Daily News

Patient Risk, Follow-up Duration Drive SAVR, TAVI Outcomes: Meta-analysis

Todd Neale

January 20, 2023

News Features

Major TAVI Studies Have ‘Methodological Issues,’ INTEGRITTY Group Contends

Michael O'Riordan

January 06, 2023

News Daily News

Top Structural Heart News of 2022

L.A. McKeown

January 06, 2023

Advertisement

Looking for a Winner Between Long-term TAVI Trials? Don’t, Experts Urge

Ross Procedure Offers ‘Excellent Survival’ 25 Years Out

Durability, Hemodynamics Look Good for SAVR, TAVI in PARTNER 3

TCT 396: Calcification Patterns in TAVR Explants: Informing Durability & Implications for Reintervention

Current Knowledge of Durability of Bioprosthetic Valves (SAVR and TAVR)

Some Surprises in Low-Risk TAVI Follow-up: PARTNER 3 and Evolut Trials

SWEDEHEART Hints at Mortality Benefit With Statins After SAVR

Balloon-Expandable Redo TAVI Shows Promise in Real-world Cohort

‘Excellent’ Outcomes With Mitral ViV Procedures, Even in Lower-Risk Patients

SAPIEN 3 TAVR Durability

What Do We Actually Know About Bioprosthetic Valve Durability (SAVR and TAVR)

Five-Year PORTICO IDE Data Reassure on Outcomes, Hemodynamics

Self-Expanding TAVI Holds Up to Surgery Out to 3 Years in Low-Risk Patients

New Durability Definitions Still Give Self-Expanding TAVI an Edge vs SAVR

FDA Alert: Possible Early Deterioration of Abbott Trifecta SAVR Valves

Patient Risk, Follow-up Duration Drive SAVR, TAVI Outcomes: Meta-analysis

Major TAVI Studies Have ‘Methodological Issues,’ INTEGRITTY Group Contends

Top Structural Heart News of 2022

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content